Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

Jorge Garcia, MD
Published: Monday, Jul 31, 2017



Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

This randomized phase III study randomized patients to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo or ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Garcia says that LATITUDE has changed the standard of care—adding abiraterone upfront has helped patients live longer, and has reduced the risk of relapse.
 


Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

This randomized phase III study randomized patients to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo or ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Garcia says that LATITUDE has changed the standard of care—adding abiraterone upfront has helped patients live longer, and has reduced the risk of relapse.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x